Months after massive Ipsen deal, BAKX Therapeutics nets more cash for its ‘Thelma and Louise’ approach to cancer cell death

BAKX Therapeutics emerged from stealth in a big way back in July, striking an $852 million deal with Ipsen for its lead cancer candidate, a small molecule designed to activate the body’s natural process for programmed cell death. And Ipsen’s putting a bit more cash in the company’s coffers...

Click to view original post